Novo Nordisk's Wegovy Weight-Loss Pill Performing Strongly -- Market Talk

Dow Jones05-04 17:02

0901 GMT - Novo Nordisk's Wegovy weight-loss pill continues to perform strongly, despite the launch of Eli Lilly's rival Foundayo pill, SB1 Markets's Johan Unnerus writes in a note. Weekly data indicates that in its third week since launching Foundayo is significantly lagging in uptake, while oral Wegovy continues to grow, he says. "The market expects Foundayo to outperform oral Wegovy by a good margin in the long term, but early developments indicate the opposite." SB1 Markets says this strengthens its view that oral Wegovy can maintain a leading position for longer than expected. In the coming week, the Danish drugmaker will also launch an oral diabetes treatment under the Ozempic brand that could bolster the company's position within diabetes. Shares rise 0.5%. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

May 04, 2026 05:02 ET (09:02 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment